HALCION (triazolam) by Pfizer is benzodiazepine. First approved in 1982.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
HALCION (triazolam) is a short-acting benzodiazepine approved in 1982 for the short-term treatment of insomnia. It works by binding to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep onset. The drug is administered orally as a tablet and remains a DEA Schedule IV controlled substance.
Product is in mature/declining phase with minimal Part D claims, suggesting a shrinking commercial team and limited career growth trajectory.
benzodiazepine. Triazolam exerts its effect for the short-term treatment of insomnia through binding to the benzodiazepine site of the gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers
A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects
Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure
Worked on HALCION at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moHALCION represents a legacy asset with minimal career growth potential; roles are primarily maintenance-focused on an aging franchise with declining revenue and market share. Professionals assigned to this product should view it as a defensive, low-visibility position rather than a launch or growth opportunity.